미국의 피임용 제품 시장 규모, 점유율과 동향 분석 리포트 : 제품별, 부문 예측(2025-2033년)

U.S. Contraceptive Market Size & Trends:

The U.S. contraceptive market size was valued at USD 8.08 billion in 2024 and is expected to reach USD 12.37 billion by 2033, growing at a CAGR of 4.88% from 2025 to 2033. The increase in the use of modern contraceptives and the rise in awareness among adolescents and young people about sexual health and family planning are key factors driving growth. Moreover, government programs have led to an increase in access to contraceptives that help prevent unwanted pregnancies in teenagers.

Continued Innovation in Women's Contraceptive Health

With the increasing demand, awareness, and preference for reliable alternatives, companies are looking forward to offering safe, effective, and long-term contraceptive options to meet the evolving needs of women worldwide, leading to notable advancements and product launches.

EnilloRing: Expanding Contraceptive Choices

In October 2023, Xiromed LLC introduced EnilloRing (etonogestrel/ethinyl estradiol vaginal ring), a generic alternative to NuvaRing. This product offers long-lasting contraceptive protection and marks an important expansion of Xiromed's extensive range of women's health medications, which also feature oral contraceptives and transdermal gels.

Rob Spina, CEO of Xiromed, highlighted the impact of this launch:

"The launch of EnilloRing is an exciting milestone in Xiromed's journey to becoming a leading generic provider of women's healthcare products in the United States. We are committed to broadening and growing the availability of contraceptive options for U.S. patients."

Manufactured at Laboratorios Leon Pharma SAU in Leon, Spain, EnilloRing underscores Xiromed's dedication to leveraging cutting-edge technologies as part of Insud Pharma's commitment to advancing women's health solutions.

U.S. Contraceptive Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. contraceptive market report based on product.

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Pills
• Intrauterine Devices (IUD)
  • Hormonal IUD
  • Nonhormonal IUD
• Condoms
  • Male Condoms
  • Female Condoms
• Vaginal Ring
• Subdermal Implants
• Injectable
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
  • 1.4.6. Research Assumption
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. Objectives
  • 1.8.1. Objective - 1
  • 1.8.2. Objective - 2
  • 1.8.3. Objective - 3
• 1.9. List of Secondary Sources
• 1.10. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. U.S. Contraceptive Market
  • 2.1.1. Market Snapshot
  • 2.1.2. Segment Snapshot
    • 2.1.2.1. Product segment outlook
  • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Regulatory Framework
• 3.5. Business Environment Analysis Tools
  • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.5.1.1. Supplier power
    • 3.5.1.2. Buyer power
    • 3.5.1.3. Substitution threat
    • 3.5.1.4. Threat of new entrant
    • 3.5.1.5. Competitive rivalry
  • 3.5.2. PESTEL Analysis

Chapter 4. Product Business Analysis

• 4.1. U.S. Contraceptive Market: Product Movement Analysis
• 4.2. U.S. Contraceptive Market: Product Segment Dashboard
• 4.3. Product Movement & Market Share Analysis, 2024 & 2033
• 4.4. U.S. Contraceptive Market Estimates & Forecast, by Product
• 4.5. Pills
  • 4.5.1. Pills Market, 2021 - 2033 (USD Million)
• 4.6. Intrauterine Devices (IUD)
  • 4.6.1. Intrauterine Devices (IUD) Market, 2021 - 2033 (USD Million)
  • 4.6.2. Hormonal IUD
    • 4.6.2.1. Hormonal IUD market, 2021 - 2033 (USD Million)
  • 4.6.3. Nonhormonal IUD
    • 4.6.3.1. Nonhormonal IUD market, 2021 - 2033 (USD Million)
• 4.7. Condoms
  • 4.7.1. Condoms Market, 2021 - 2033 (USD Million)
  • 4.7.2. Male Condoms
    • 4.7.2.1. Male condoms market, 2021 - 2033 (USD Million)
  • 4.7.3. Female Condoms
    • 4.7.3.1. Female condoms market, 2021 - 2033 (USD Million)
• 4.8. Vaginal Ring
  • 4.8.1. Vaginal Ring Market, 2021 - 2033 (USD Million)
• 4.9. Subdermal Implants
  • 4.9.1. Subdermal Implants Market, 2021 - 2033 (USD Million)
• 4.10. Injectable
  • 4.10.1. Injectable Market, 2021 - 2033 (USD Million)
• 4.11. Others
  • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Company Categorization
• 5.2. Company Market Position Analysis, 2024
• 5.3. Strategy Mapping
  • 5.3.1. Mergers & Acquisitions
  • 5.3.2. Partnership and Collaborations
  • 5.3.3. New Product Launch
  • 5.3.4. Others
• 5.4. Company Profiles/Listing
  • 5.4.1. Church & Dwight Co., Inc.
    • 5.4.1.1. Overview
    • 5.4.1.2. Financial performance
    • 5.4.1.3. Product benchmarking
    • 5.4.1.4. Strategic initiatives
  • 5.4.2. Reckitt Benckiser Group Plc
    • 5.4.2.1. Overview
    • 5.4.2.2. Financial performance
    • 5.4.2.3. Product benchmarking
    • 5.4.2.4. Strategic initiatives
  • 5.4.3. Organon Group of Companies
    • 5.4.3.1. Overview
    • 5.4.3.2. Financial performance
    • 5.4.3.3. Product benchmarking
    • 5.4.3.4. Strategic initiatives
  • 5.4.4. Pfizer, Inc.
    • 5.4.4.1. Overview
    • 5.4.4.2. Financial performance
    • 5.4.4.3. Product benchmarking
    • 5.4.4.4. Strategic initiatives
  • 5.4.5. Teva Pharmaceutical Industries Ltd.
    • 5.4.5.1. Overview
    • 5.4.5.2. Financial performance
    • 5.4.5.3. Product benchmarking
    • 5.4.5.4. Strategic initiatives
  • 5.4.6. The Cooper Companies, Inc.
    • 5.4.6.1. Overview
    • 5.4.6.2. Financial performance
    • 5.4.6.3. Product benchmarking
    • 5.4.6.4. Strategic initiatives
  • 5.4.7. Agile Therapeutics
    • 5.4.7.1. Overview
    • 5.4.7.2. Financial performance
    • 5.4.7.3. Product benchmarking
    • 5.4.7.4. Strategic initiatives
  • 5.4.8. Mayer Laboratories, Inc.
    • 5.4.8.1. Overview
    • 5.4.8.2. Financial performance
    • 5.4.8.3. Product benchmarking
    • 5.4.8.4. Strategic initiatives
  • 5.4.9. Mayne Pharma Group Limited.
    • 5.4.9.1. Overview
    • 5.4.9.2. Financial performance
    • 5.4.9.3. Product benchmarking
    • 5.4.9.4. Strategic initiatives
  • 5.4.10. Bayer AG
    • 5.4.10.1. Overview
    • 5.4.10.2. Financial performance
    • 5.4.10.3. Product benchmarking
    • 5.4.10.4. Strategic initiatives
  • 5.4.11. Afaxys, Inc.
    • 5.4.11.1. Overview
    • 5.4.11.2. Financial performance
    • 5.4.11.3. Product benchmarking
    • 5.4.11.4. Strategic initiatives
  • 5.4.12. AbbVie
    • 5.4.12.1. Overview
    • 5.4.12.2. Financial performance
    • 5.4.12.3. Product benchmarking
    • 5.4.12.4. Strategic initiatives
  • 5.4.13. Gedeon Richter
    • 5.4.13.1. Overview
    • 5.4.13.2. Financial performance
    • 5.4.13.3. Product benchmarking
    • 5.4.13.4. Strategic initiatives